Adenovirus-Based Immunotherapy of Cancer: Promises to Keep

Advances in Cancer Research

Volumn 115, Issue , 2012, Pages 147-220

  De Gruijl, Tanja D ^a   Van De Ven, Rieneke ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b EARLE A CHILES RESEARCH INSTITUTE   (United States)

Author keywords

Adenovirus; Cancer; Dendritic cell targeting; Immunotherapy; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTEGRIN; B7 ANTIGEN; CANCER VACCINE; CD40 LIGAND; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DRUG VEHICLE; GAMMA INTERFERON; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 12P70; MELAN A; MEMBRANE COFACTOR PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; ONCOLYTIC ADENOVIRUS; PROSTATE SPECIFIC ANTIGEN; STAT3 PROTEIN; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VIRUS VACCINE; CAPSID PROTEIN;

ADAPTIVE IMMUNITY; ADENOVIRUS; ANGIOGENESIS; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL DEATH; CELL DIFFERENTIATION; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR IMMUNITY; CROSS PRESENTATION; CYTOKINE RELEASE; DENDRITIC CELL; DISTANT METASTASIS; DNA IMMUNIZATION; DNA MODIFICATION; DRUG EFFICACY; DRUG TARGETING; GENE TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO GENE TRANSFER; IN VIVO STUDY; INNATE IMMUNITY; LONG TERM MEMORY; LYMPHOCYTE PROLIFERATION; MOLECULAR RECOGNITION; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SEROTYPE; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION INITIATION; TRANSGENE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR REJECTION; UTERINE CERVIX CANCER; VIRAL GENE DELIVERY SYSTEM; VIRAL TROPISM; VIRUS CAPSID; VIRUS REPLICATION; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); CYTOLOGY; GENE THERAPY; GENE VECTOR; GENETIC ENGINEERING; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; MOUSE; NEOPLASM; REVIEW; SERODIAGNOSIS;

ADENOVIRIDAE; ANIMALS; CANCER VACCINES; CAPSID PROTEINS; CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; GENETIC ENGINEERING; GENETIC THERAPY; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; MICE; NEOPLASMS; NEUTRALIZATION TESTS;

EID: 84866780434     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-398342-8.00006-9     Document Type: Chapter

References (450)

1. Abbink P., Lemckert A.A.C., Ewald B.A., Lynch D.M., Denholtz M., Smits S., et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. Journal of Virology 2007, 81:4654-4663.
2. Adams W.C., Bond E., Havenga M.J.E., Holterman L., Goudsmit J., Karlsson Hedestam G.B., et al. Adenovirus serotype 5 infects human dendritic cells via a coxsackievirus-adenovirus receptor-independent receptor pathway mediated by lactoferrin and DC-SIGN. The Journal of General Virology 2009, 90:1600-1610.
3. Adams W.C., Gujer C., McInerney G., Gall J.G.D., Petrovas C., Karlsson Hedestam G.B., et al. Adenovirus type-35 vectors block human CD4+ T-cell activation via CD46 ligation. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:7499-7504.
4. Akbari O., Panjwani N., Garcia S., Tascon R., Lowrie D., Stockinger B. DNA vaccination: Transfection and activation of dendritic cells as key events for immunity. The Journal of Experimental Medicine 1999, 189:169-178.
5. Akbulut H., Tang Y., Akbulut K.G., Maynard J., Deisseroth A. Addition of adenoviral vector targeting of chemotherapy to the MUC-1/ecdCD40L VPPP vector prime protein boost vaccine prolongs survival of mice carrying growing subcutaneous deposits of Lewis lung cancer cells. Gene Therapy 2010, 17:1333-1340.
6. Alcock R., Cottingham M.G., Rollier C.S., Furze J., De Costa S.D., Hanlon M., et al. Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass. Science Translational Medicine 2010, 2:19ra12.
7. Amalfitano A., Hauser M.A., Hu H., Serra D., Begy C.R., Chamberlain J.S. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. Journal of Virology 1998, 72:926-933.
8. Andarini S., Kikuchi T., Nukiwa M., Pradono P., Suzuki T., Ohkouchi S., et al. Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts. Cancer Research 2004, 64:3281-3287.
9. Appledorn D.M., Patial S., McBride A., Godbehere S., van Rooijen N., Parameswaran N., et al. Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo. Journal of Immunology 2008, 181:2134-2144.
10. Aranda F., Llopiz D., Díaz-Valdés N., Riezu-Boj J.I., Bezunartea J., Ruiz M., et al. Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors. Cancer Research 2011, 71:3214-3224.
11. Arnberg N. Adenovirus receptors: Implications for tropism, treatment and targeting. Reviews in Medical Virology 2009, 19:165-178.
12. Arnberg N., Edlund K., Kidd A.H., Wadell G. Adenovirus type 37 uses sialic acid as a cellular receptor. Journal of Virology 2000, 74:42-48.
13. Arnberg N., Kidd A.H., Edlund K., Olfat F., Wadell G. Initial interactions of subgenus D adenoviruses with A549 cellular receptors: Sialic acid versus alpha(v) integrins. Journal of Virology 2000, 74:7691-7693.
14. Arribillaga L., Sarobe P., Arina A., Gorraiz M., Borrás-Cuesta F., Ruiz J., et al. Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus. Vaccine 2005, 23:3493-3499.
15. Arthur J.F., Butterfield L.H., Roth M.D., Bui L.A., Kiertscher S.M., Lau R., et al. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Therapy 1997, 4:17-25.
16. Bachem A., Güttler S., Hartung E., Ebstein F., Schaefer M., Tannert A., et al. Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. The Journal of Experimental Medicine 2010, 207:1273-1281.
17. Bachtarzi H., Stevenson M., Šubr V., Seymour L.W., Fisher K.D. E-selectin is a viable route of infection for polymer-coated adenovirus retargeting in TNF-α-activated human umbilical vein endothelial cells. Journal of Drug Targeting 2011, 19:690-700.
18. Bachtarzi H., Stevenson M., Šubr V., Ulbrich K., Seymour L.W., Fisher K.D. Targeting adenovirus gene delivery to activated tumour-associated vasculature via endothelial selectins. Journal of Controlled Release 2011, 150:196-203.
19. Backer R., Schwandt T., Greuter M., Oosting M., Jüngerkes F., Tüting T., et al. Effective collaboration between marginal metallophilic macrophages and CD8+ dendritic cells in the generation of cytotoxic T cells. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:216-221.
20. Bai M., Harfe B., Freimuth P. Mutations that alter an Arg-Gly-Asp (RGD) sequence in the adenovirus type 2 penton base protein abolish its cell-rounding activity and delay virus reproduction in flat cells. Journal of Virology 1993, 67:5198-5205.
21. Balakireva L., Schoehn G., Thouvenin E., Chroboczek J. Binding of adenovirus capsid to dipalmitoyl phosphatidylcholine provides a novel pathway for virus entry. Journal of Virology 2003, 77:4858-4866.
22. Baratelli F., Takedatsu H., Hazra S., Peebles K., Luo J., Kurimoto P.S., et al. Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancer. Journal of Translational Medicine 2008, 6:38.
23. Barlan A.U., Griffin T.M., McGuire K.A., Wiethoff C.M. Adenovirus membrane penetration activates the NLRP3 inflammasome. Journal of Virology 2011, 85:146-155.
24. Barouch D.H., Kik S.V., Weverling G.J., Dilan R., King S.L., Maxfield L.F., et al. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 2011, 29:5203-5209.
25. Basner-Tschakarjan E., Gaffal E., O'Keeffe M., Tormo D., Limmer A., Wagner H., et al. Adenovirus efficiently transduces plasmacytoid dendritic cells resulting in TLR9-dependent maturation and IFN-alpha production. The Journal of Gene Medicine 2006, 8:1300-1306.
26. Bassett J.D., Swift S.L., Vanseggelen H., Hammill J.A., McGray A.R., Evelegh C., et al. Combined mTOR inhibition and OX40 agonism enhances CD8(+) T cell memory and protective immunity produced by recombinant adenovirus vaccines. Molecular Therapy 2012, 20:860-869.
27. Beatty G.L., Chiorean E.G., Fishman M.P., Saboury B., Teitelbaum U.R., Sun W., et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331:1612-1616.
28. Beer S.J., Matthews C.B., Stein C.S., Ross B.D., Hilfinger J.M., Davidson B.L. Poly (lactic-glycolic) acid copolymer encapsulation of recombinant adenovirus reduces immunogenicity in vivo. Gene Therapy 1998, 5:740-746.
29. Belousova N., Korokhov N., Krendelshchikova V., Simonenko V., Mikheeva G., Triozzi P.L., et al. Genetically targeted adenovirus vector directed to CD40-expressing cells. Journal of Virology 2003, 77:11367-11377.
30. Belousova N., Krendelchtchikova V., Curiel D.T., Krasnykh V. Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein. Journal of Virology 2002, 76:8621-8631.
31. Bennett S.R., Carbone F.R., Karamalis F., Flavell R.A., Miller J.F., Heath W.R. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998, 393:478-480.
32. Bergelson J.M., Cunningham J.A., Droguett G., Kurt-Jones E.A., Krithivas A., Hong J.S., et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997, 275:1320-1323.
33. Bernt K.M., Ni S., Tieu A.-T., Lieber A. Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy. Cancer Research 2005, 65:4343-4352.
34. Bett A.J., Dubey S.A., Mehrotra D.V., Guan L., Long R., Anderson K., et al. Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans. Vaccine 2010, 28:7881-7889.
35. Bett A.J., Haddara W., Prevec L., Graham F.L. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:8802-8806.
36. Bett A.J., Prevec L., Graham F.L. Packaging capacity and stability of human adenovirus type 5 vectors. Journal of Virology 1993, 67:5911-5921.
37. Bharadwaj U., Li M., Zhang R., Chen C., Yao Q. Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell differentiation and activation. Cancer Research 2007, 67:5479-5488.
38. Bonkobara M., Zukas P.K., Shikano S., Nakamura S., Cruz P.D., Ariizumi K. Epidermal Langerhans cell-targeted gene expression by a dectin-2 promoter. Journal of Immunology 2001, 167:6893-6900.
39. Bouwhuis M.G., Ten Hagen T.L., Suciu S., Eggermont A.M. Autoimmunity and treatment outcome in melanoma. Current Opinion in Oncology 2011, 23:170-176.
40. Bradshaw A.C., Parker A.L., Duffy M.R., Coughlan L., van Rooijen N., Kähäri V.-M., et al. Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X. PLoS Pathogens 2010, 6:e1001142.
41. Brahmer J.R., Drake C.G., Wollner I., Powderly J.D., Picus J., Sharfman W.H., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. Journal of Clinical Oncology 2010, 28:3167-3175.
42. Brandão J.G., Scheper R.J., Lougheed S.M., Curiel D.T., Tillman B.W., Gerritsen W.R., et al. CD40-targeted adenoviral gene transfer to dendritic cells through the use of a novel bispecific single-chain Fv antibody enhances cytotoxic T cell activation. Vaccine 2003, 21:2268-2272.
43. Bråve A., Ljungberg K., Wahren B., Liu M.A. Vaccine delivery methods using viral vectors. Molecular Pharmaceutics 2007, 4:18-32.
44. Bromberg J. Stat proteins and oncogenesis. The Journal of Clinical Investigation 2002, 109:1139-1142.
45. Bros M., Ross X.-L., Pautz A., Reske-Kunz A.B., Ross R. The human fascin gene promoter is highly active in mature dendritic cells due to a stage-specific enhancer. Journal of Immunology 2003, 171:1825-1834.
46. Brouwer E., Havenga M.J., Ophorst O., de Leeuw B., Gijsbers L., Gillissen G., et al. Human adenovirus type 35 vector for gene therapy of brain cancer: Improved transduction and bypass of pre-existing anti-vector immunity in cancer patients. Cancer Gene Therapy 2007, 14:211-219.
47. Brower V. Approval of provenge seen as first step for cancer treatment vaccines. Journal of the National Cancer Institute 2010, 102:1108-1110.
48. Bru T., Salinas S., Kremer E.J. An update on canine adenovirus type 2 and its vectors. Viruses 2010, 2:2134-2153.
49. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. The Lancet 2008, 372:1881-1893.
50. Burnet M. Cancer; a biological approach. I. The processes of control. British Medical Journal 1957, 1:779-786.
51. Burnet F.M. The concept of immunological surveillance. Progress in Experimental Tumor Research 1970, 13:1-27.
52. Butterfield L.H., Comin-Anduix B., Vujanovic L., Lee Y., Dissette V.B., Yang J.-Q., et al. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. Journal of Immunotherapy 2008, 31:294-309.
53. Butterfield L.H., Vujanovic L. New approaches to the development of adenoviral dendritic cell vaccines in melanoma. Current Opinion in Investigational Drugs 2010, 11:1399-1408.
54. Campos S.K., Parrott M.B., Barry M.A. Avidin-based targeting and purification of a protein IX-modified, metabolically biotinylated adenoviral vector. Molecular Therapy 2004, 9:942-954.
55. Carlisle R.C., Di Y., Cerny A.M., Sonnen A.F.P., Sim R.B., Green N.K., et al. Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood 2009, 113:1909-1918.
56. Casal M., Haskins M. Large animal models and gene therapy. European Journal of Human Genetics 2006, 14:266-272.
57. Cerullo V., Seiler M.P., Mane V., Brunetti-Pierri N., Clarke C., Bertin T.K., et al. Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors. Molecular Therapy 2007, 15:378-385.
58. Chen Z., Mok H., Pflugfelder S.C., Li D.-Q., Barry M.A. Improved transduction of human corneal epithelial progenitor cells with cell-targeting adenoviral vectors. Experimental Eye Research 2006, 83:798-806.
59. Chen C.Y., Senac J.S., Weaver E.A., May S.M., Jelinek D.F., Greipp P., et al. Species D adenoviruses as oncolytics against B-cell cancers. Clinical Cancer Research 2011, 17:6712-6722.
60. Cheng C., Gall J.G.D., Kong W.-P., Sheets R.L., Gomez P.L., King C.R., et al. Mechanism of Ad5 vaccine immunity and toxicity: Fiber shaft targeting of dendritic cells. PLoS Pathogens 2007, 3:e25.
61. Cheong S.C., Wang Y., Meng J.-H., Hill R., Sweeney K., Kirn D., et al. E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models. Cancer Gene Therapy 2008, 15:40-50.
62. Chiappori A.A., Soliman H., Janssen W.E., Antonia S.J., Gabrilovich D.I. INGN-225: A dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: Observed association between immune response and enhanced chemotherapy effect. Expert Opinion on Biological Therapy 2010, 10:983-991.
63. Chillón M., Lee J.H., Fasbender A., Welsh M.J. Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro. Gene Therapy 1998, 5:995-1002.
64. Choi K.-J., Kim J.-H., Lee Y.-S., Kim J., Suh B.-S., Kim H., et al. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. Gene Therapy 2006, 13:1010-1020.
65. Choi K.J., Zhang S.N., Choi I.K., Kim J.S., Yun C.O. Strengthening of antitumor immune memory and prevention of thymic atrophy mediated by adenovirus expressing IL-12 and GM-CSF. Gene Therapy 2011, (epub).
66. Chu Y., Heistad D., Cybulsky M.I., Davidson B.L. Vascular cell adhesion molecule-1 augments adenovirus-mediated gene transfer. Arteriosclerosis, Thrombosis, and Vascular Biology 2001, 21:238-242.
67. Churchyard G.J., Morgan C., Adams E., Hural J., Graham B.S., Moodie Z., et al. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One 2011, 6:e21225.
68. Clive K.S., Tyler J.A., Clifton G.T., Holmes J.P., Mittendorf E.A., Ponniah S., et al. Use of GM-CSF as an adjuvant with cancer vaccines: Beneficial or detrimental?. Expert Review of Vaccines 2010, 9:519-525.
69. Corjon S., Gonzalez G., Henning P., Grichine A., Lindholm L., Boulanger P., et al. Cell entry and trafficking of human adenovirus bound to blood factor X is determined by the fiber serotype and not hexon:heparan sulfate interaction. PLoS One 2011, 6:e18205.
70. Crompton J., Toogood C.I., Wallis N., Hay R.T. Expression of a foreign epitope on the surface of the adenovirus hexon. The Journal of General Virology 1994, 75(Pt. 1):133-139.
71. Crozat K., Guiton R., Contreras V., Feuillet V., Dutertre C.-A., Ventre E., et al. The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells. The Journal of Experimental Medicine 2010, 207:1283-1292.
72. Danthinne X., Imperiale M.J. Production of first generation adenovirus vectors: A review. Gene Therapy 2000, 7:1707-1714.
73. de Gruijl T.D., Luykx-de Bakker S.A., Tillman B.W., van den Eertwegh A.J.M., Buter J., Lougheed S.M., et al. Prolonged maturation and enhanced transduction of dendritic cells migrated from human skin explants after in situ delivery of CD40-targeted adenoviral vectors. Journal of Immunology 2002, 169:5322-5331.
74. de Gruijl T.D., Ophorst O.J.A.E., Goudsmit J., Verhaagh S., Lougheed S.M., Radosevic K., et al. Intradermal delivery of adenoviral type-35 vectors leads to high efficiency transduction of mature, CD8+ T cell-stimulating skin-emigrated dendritic cells. Journal of Immunology 2006, 177:2208-2215.
75. de Gruijl T.D., Sombroek C.C., Lougheed S.M., Oosterhoff D., Buter J., van den Eertwegh A.J.M., et al. A postmigrational switch among skin-derived dendritic cells to a macrophage-like phenotype is predetermined by the intracutaneous cytokine balance. Journal of Immunology 2006, 176:7232-7242.
76. de Jong J.C., Osterhaus A.D.M.E., Jones M.S., Harrach B. Human adenovirus type 52: A type 41 in disguise?. Journal of Virology 2008, 82:3809. author reply 3809-3810.
77. De Rosa S.C., Thomas E.P., Bui J., Huang Y., deCamp A., Morgan C., et al. HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable. Journal of Immunology 2011, 187:3391-3401.
78. de Vrij J., Uil T.G., van den Hengel S.K., Cramer S.J., Koppers-Lalic D., Verweij M.C., et al. Adenovirus targeting to HLA-A1/MAGE-A1-positive tumor cells by fusing a single-chain T-cell receptor with minor capsid protein IX. Gene Therapy 2008, 15:978-989.
79. Dechecchi M.C., Melotti P., Bonizzato A., Santacatterina M., Chilosi M., Cabrini G. Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. Journal of Virology 2001, 75:8772-8780.
80. Dechecchi M.C., Tamanini A., Bonizzato A., Cabrini G. Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions. Virology 2000, 268:382-390.
81. DeFrancesco L. Landmark approval for Dendreon's cancer vaccine. Nature Biotechnology 2010, 28:531-532.
82. Dehari H., Ito Y., Nakamura T., Kobune M., Sasaki K., Yonekura N., et al. Enhanced antitumor effect of RGD fiber-modified adenovirus for gene therapy of oral cancer. Cancer Gene Therapy 2003, 10:75-85.
83. Diaconu I., Cerullo V., Hirvinen M.L., Escutenaire S., Ugolini M., Pesonen S.K., et al. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Research 2012, 72:2327-2338.
84. Dias J.D., Hemminki O., Diaconu I., Hirvinen M., Bonetti A., Guse K., et al. Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. Gene Therapy 2011, (Epub ahead of print). 10.1038/gt.2011.176.
85. Dietz A.B., Vuk-Pavlović S. High efficiency adenovirus-mediated gene transfer to human dendritic cells. Blood 1998, 91:392-398.
86. Ding Z.-Y., Wu Y., Luo Y., Su J.-M., Li Q., Zhang X.-W., et al. Mannan-modified adenovirus as a vaccine to induce antitumor immunity. Gene Therapy 2007, 14:657-663.
87. Dmitriev I.P., Kashentseva E.A., Curiel D.T. Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX. Journal of Virology 2002, 76:6893-6899.
88. Dmitriev I., Kashentseva E., Rogers B.E., Krasnykh V., Curiel D.T. Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. Journal of Virology 2000, 74:6875-6884.
89. Dmitriev I., Krasnykh V., Miller C.R., Wang M., Kashentseva E., Mikheeva G., et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. Journal of Virology 1998, 72:9706-9713.
90. Dörig R.E., Marcil A., Richardson C.D. CD46, a primate-specific receptor for measles virus. Trends in Microbiology 1994, 2:312-318.
91. Dormond E., Kamen A.A. Manufacturing of adenovirus vectors: Production and purification of helper dependent adenovirus. Methods in Molecular Biology 2011, 737:139-156.
92. Dormond E., Perrier M., Kamen A. From the first to the third generation adenoviral vector: What parameters are governing the production yield?. Biotechnology Advances 2009, 27:133-144.
93. Douglas A.D., de Cassan S.C., Dicks M.D.J., Gilbert S.C., Hill A.V.S., Draper S.J. Tailoring subunit vaccine immunogenicity: Maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1. Vaccine 2010, 28:7167-7178.
94. Douglas J.T., Rogers B.E., Rosenfeld M.E., Michael S.I., Feng M., Curiel D.T. Targeted gene delivery by tropism-modified adenoviral vectors. Nature Biotechnology 1996, 14:1574-1578.
95. Dranoff G. GM-CSF-secreting melanoma vaccines. Oncogene 2003, 22:3188-3192.
96. Draper S.J., Biswas S., Spencer A.J., Remarque E.J., Capone S., Naddeo M., et al. Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines. Journal of Immunology 2010, 185:7583-7595.
97. Dreier B., Mikheeva G., Belousova N., Parizek P., Boczek E., Jelesarov I., et al. Her2-specific multivalent adapters confer designed tropism to adenovirus for gene targeting. Journal of Molecular Biology 2011, 405:410-426.
98. Dresch C., Edelmann S.L., Marconi P., Brocker T. Lentiviral-mediated transcriptional targeting of dendritic cells for induction of T cell tolerance in vivo. Journal of Immunology 2008, 181:4495-4506.
99. Dummer R., Eichmüller S., Gellrich S., Assaf C., Dreno B., Schiller M., et al. Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas. Molecular Therapy 2010, 18:1244-1247.
100. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: From immunosurveillance to tumor escape. Nature Immunology 2002, 3:991-998.
101. Edukulla R., Ramakrishna E., Woller N., Mundt B., Knocke S., Gürlevik E., et al. Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses. Cancer Research 2009, 69:1448-1458.
102. Eiz B., Pring-Akerblom P. Molecular characterization of the type-specific gamma-determinant located on the adenovirus fiber. Journal of Virology 1997, 71:6576-6581.
103. Fallaux F.J., Bout A., van der Velde I., van den Wollenberg D.J., Hehir K.M., Keegan J., et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Human Gene Therapy 1998, 9:1909-1917.
104. Fallaux F.J., Kranenburg O., Cramer S.J., Houweling A., Van Ormondt H., Hoeben R.C., et al. Characterization of 911: A new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Human Gene Therapy 1996, 7:215-222.
105. Fechner H., Haack A., Wang H., Wang X., Eizema K., Pauschinger M., et al. Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Therapy 1999, 6:1520-1535.
106. Fernandes M.S., Gomes E.M., Butcher L.D., Hernandez-Alcoceba R., Chang D., Kansopon J., et al. Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene. Clinical Cancer Research 2009, 15:4847-4856.
107. Finnefrock A.C., Tang A., Li F., Freed D.C., Feng M., Cox K.S., et al. PD-1 blockade in rhesus macaques: Impact on chronic infection and prophylactic vaccination. Journal of Immunology 2009, 182:980-987.
108. Fisher K.D., Stallwood Y., Green N.K., Ulbrich K., Mautner V., Seymour L.W. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Therapy 2001, 8:341-348.
109. Flinsenberg T.W.H., Compeer E.B., Boelens J.J., Boes M. Antigen cross-presentation: Extending recent laboratory findings to therapeutic intervention. Clinical and Experimental Immunology 2011, 165:8-18.
110. Fox B.A., Schendel D.J., Butterfield L.H., Aamdal S., Allison J.P., Ascierto P.A., et al. Defining the critical hurdles in cancer immunotherapy. Journal of Translational Medicine 2011, 9:214.
111. Fransen M.F., Sluijter M., Morreau H., Arens R., Melief C.J.M. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clinical Cancer Research 2011, 17:2270-2280.
112. Fukuhara H., Homma Y., Todo T. Oncolytic virus therapy for prostate cancer. International Journal of Urology 2010, 17:20-30.
113. Fushimi T., O'Connor T.P., Crystal R.G. Adenoviral gene transfer of stromal cell-derived factor-1 to murine tumors induces the accumulation of dendritic cells and suppresses tumor growth. Cancer Research 2006, 66:3513-3522.
114. Gabitzsch E.S., Xu Y., Balcaitis S., Balint J.P., Jones F.R. An Ad5[E1-, E2b-]-HER2/neu vector induces immune responses and inhibits HER2/neu expressing tumor progression in Ad5 immune mice. Cancer Gene Therapy 2011, 18:326-335.
115. Gabitzsch E.S., Xu Y., Balint J.P., Hartman Z.C., Lyerly H.K., Jones F.R. Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA. Cancer Immunology, Immunotherapy 2010, 59:1131-1135.
116. Gabitzsch E.S., Xu Y., Yoshida L.H., Balint J., Gayle R.B., Amalfitano A., et al. A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses. Immunology Letters 2009, 122:44-51.
117. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nature Reviews. Immunology 2004, 4:941-952.
118. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nature Reviews. Immunology 2009, 9:162-174.
119. Gaggar A., Shayakhmetov D.M., Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nature Medicine 2003, 9:1408-1412.
120. Gajewski T.F., Fuertes M., Spaapen R., Zheng Y., Kline J. Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Current Opinion in Immunology 2011, 23:286-292.
121. Gall J.G., Crystal R.G., Falck-Pedersen E. Construction and characterization of hexon-chimeric adenoviruses: Specification of adenovirus serotype. Journal of Virology 1998, 72:10260-10264.
122. Gambotto A., Tuting T., McVey D.L., Kovesdi I., Tahara H., Lotze M.T., et al. Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12. Cancer Gene Therapy 1999, 6:45-53.
123. Gao J.-Q., Kanagawa N., Xu D.-H., Han M., Sugita T., Hatanaka Y., et al. Combination of two fiber-mutant adenovirus vectors, one encoding the chemokine FKN and another encoding cytokine interleukin 12, elicits notably enhanced anti-tumor responses. Cancer Immunology, Immunotherapy 2008, 57:1657-1664.
124. Geisbert T.W., Bailey M., Hensley L., Asiedu C., Geisbert J., Stanley D., et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. Journal of Virology 2011, 85:4222-4233.
125. Gerlini G., Mariotti G., Chiarugi A., Di Gennaro P., Caporale R., Parenti A., et al. Induction of CD83+CD14+ nondendritic antigen-presenting cells by exposure of monocytes to IFN-alpha. Journal of Immunology 2008, 181:2999-3008.
126. Gigante M., Mandic M., Wesa A.K., Cavalcanti E., Dambrosio M., Mancini V., et al. Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients. Journal of Immunotherapy 2008, 31:254-262.
127. Glasgow J.N., Mikheeva G., Krasnykh V., Curiel D.T. A strategy for adenovirus vector targeting with a secreted single chain antibody. PLoS One 2009, 4:e8355.
128. Glaspy J., Ribas A., Chmielowski B. Interferon alfa in the postsurgical management of high-risk melanoma: Is it worth it?. Journal of Clinical Oncology 2009, 27:2896-2897.
129. Gonzalez R., Vereecque R., Wickham T.J., Facon T., Hetuin D., Kovesdi I., et al. Transduction of bone marrow cells by the AdZ.F(pK7) modified adenovirus demonstrates preferential gene transfer in myeloma cells. Human Gene Therapy 1999, 10:2709-2717.
130. Gorziglia M.I., Lapcevich C., Roy S., Kang Q., Kadan M., Wu V., et al. Generation of an adenovirus vector lacking E1, e2a, E3, and all of E4 except open reading frame 3. Journal of Virology 1999, 73:6048-6055.
131. Grabbe S., Bruvers S., Granstein R.D. Effects of immunomodulatory cytokines on the presentation of tumor-associated antigens by epidermal Langerhans cells. The Journal of Investigative Dermatology 1992, 99:66S-68S.
132. Graham F.L., Smiley J., Russell W.C., Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. The Journal of General Virology 1977, 36:59-74.
133. Gray G., Buchbinder S., Duerr A. Overview of STEP and Phambili trial results: Two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Current Opinion in HIV and AIDS 2010, 5:357-361.
134. Grossmann C., Tenbusch M., Nchinda G., Temchura V., Nabi G., Stone G.W., et al. Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands. BMC Immunology 2009, 10:43.
135. Günther P.S., Mikeler E., Hamprecht K., Schneider-Schaulies J., Jahn G., Dennehy K.M. CD209/DC-SIGN mediates efficient infection of monocyte-derived dendritic cells by clinical adenovirus 2C isolates in the presence of bovine lactoferrin. The Journal of General Virology 2011, 92:1754-1759.
136. Gupalo E., Buriachkovskaia L., Othman M. Human platelets express CAR with localization at the sites of intercellular interaction. Virology Journal 2011, 8:456.
137. Haenssle H., Buhl T., Knudsen S., Krueger U., Rosenberger A., Reich K., et al. CD40 ligation during dendritic cell maturation reduces cell death and prevents interleukin-10-induced regression to macrophage-like monocytes. Experimental Dermatology 2008, 17:177-187.
138. Halldén G., Hill R., Wang Y., Anand A., Liu T.-C., Lemoine N.R., et al. Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy. Molecular Therapy 2003, 8:412-424.
139. Han Z., Hong Z., Chen C., Gao Q., Luo D., Fang Y., et al. A novel oncolytic adenovirus selectively silences the expression of tumor-associated STAT3 and exhibits potent antitumoral activity. Carcinogenesis 2009, 30:2014-2022.
140. Hangalapura B.N., Oosterhoff D., Aggarwal S., Wijnands P.G.J.T.B., van de Ven R., Santegoets S.J.A.M., et al. Selective transduction of dendritic cells in human lymph nodes and superior induction of high-avidity melanoma-reactive cytotoxic T cells by a CD40-targeted adenovirus. Journal of Immunotherapy 2010, 33:706-715.
141. Hangalapura B.N., Oosterhoff D., de Groot J., Boon L., Tüting T., van den Eertwegh A.J., et al. Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine. Cancer Research 2011, 71:5827-5837.
142. Hangalapura B.N., Oosterhoff D., Gupta T., de Groot J., Wijnands P.G., van Beusechem V.W., et al. Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine. Vaccine 2011, 29:2313-2321.
143. Hangalapura B.N., Timares L., Oosterhoff D., Scheper R.J., Curiel D.T., de Gruijl T.D. CD40-targeted adenoviral cancer vaccines: The long and winding road to the clinic. The Journal of Gene Medicine 2012.
144. Hara H., Kobayashi A., Narumi K., Kondoh A., Yoshida K., Nishimoto T., et al. Intratumoral interferon-alpha gene transfer enhances tumor immunity after allogeneic hematopoietic stem cell transplantation. Cancer Immunology, Immunotherapy 2009, 58:1007-1021.
145. Hara H., Kobayashi A., Yoshida K., Ohashi M., Ohnami S., Uchida E., et al. Local interferon-alpha gene therapy elicits systemic immunity in a syngeneic pancreatic cancer model in hamster. Cancer Science 2007, 98:455-463.
146. Harrop R., John J., Carroll M.W. Recombinant viral vectors: Cancer vaccines. Advanced Drug Delivery Reviews 2006, 58:931-947.
147. Hartman Z.C., Kiang A., Everett R.S., Serra D., Yang X.Y., Clay T.M., et al. Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo. Journal of Virology 2007, 81:1796-1812.
148. Hartman Z.C., Osada T., Glass O., Yang X.Y., Lei G.-J., Lyerly H.K., et al. Ligand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunity. Cancer Research 2010, 70:7209-7220.
149. Harui A., Roth M.D., Sanghvi M., Vira D., Mizuguchi H., Basak S.K. Centrifugation enhances integrin-mediated transduction of dendritic cells by conventional and RGD-modified adenoviral vectors. Journal of Immunological Methods 2006, 312:94-104.
150. Harui A., Roth M.D., Vira D., Sanghvi M., Mizuguchi H., Basak S.K. Adenoviral-encoded antigens are presented efficiently by a subset of dendritic cells expressing high levels of alpha(v)beta3 integrins. Journal of Leukocyte Biology 2006, 79:1271-1278.
151. Harvey T.J., Burdon D., Steele L., Ingram N., Hall G.D., Selby P.J., et al. Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor. Gene Therapy 2010, 17:1000-1010.
152. Heath W.R., Carbone F.R. Cross-presentation, dendritic cells, tolerance and immunity. Annual Review of Immunology 2001, 19:47-64.
153. Hensbergen P.J., Wijnands P.G.J.T.B., Schreurs M.W.J., Scheper R.J., Willemze R., Tensen C.P. The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis. Journal of Immunotherapy 2005, 28:343-351.
154. Hensley S.E., Amalfitano A. Toll-like receptors impact on safety and efficacy of gene transfer vectors. Molecular Therapy 2007, 15:1417-1422.
155. Higham E.M., Shen C.-H., Wittrup K.D., Chen J. Cutting edge: Delay and reversal of T cell tolerance by intratumoral injection of antigen-loaded dendritic cells in an autochthonous tumor model. Journal of Immunology 2010, 184:5954-5958.
156. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine 2010, 363:711-723.
157. Holterman L., Vogels R., van der Vlugt R., Sieuwerts M., Grimbergen J., Kaspers J., et al. Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: Low seroprevalence and non-cross-reactivity with Ad5. Journal of Virology 2004, 78:13207-13215.
158. Hong S.S., Karayan L., Tournier J., Curiel D.T., Boulanger P.A. Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface of human epithelial and B lymphoblastoid cells. The EMBO Journal 1997, 16:2294-2306.
159. Hsu C., Boysen M., Gritton L.D., Frosst P.D., Nemerow G.R., Von Seggern D.J. In vitro dendritic cell infection by pseudotyped adenoviral vectors does not correlate with their in vivo immunogenicity. Virology 2005, 332:1-7.
160. Huang S., Kamata T., Takada Y., Ruggeri Z.M., Nemerow G.R. Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cells. Journal of Virology 1996, 70:4502-4508.
161. Huang J.-H., Zhang S.-N., Choi K.-J., Choi I.-K., Kim J.-H., Lee M.-G., et al. Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL. Molecular Therapy 2010, 18:264-274.
162. Ichikawa H.T., Williams L.P., Segal B.M. Activation of APCs through CD40 or Toll-like receptor 9 overcomes tolerance and precipitates autoimmune disease. Journal of Immunology 2002, 169:2781-2787.
163. Iida T., Shiba H., Misawa T., Ohashi T., Eto Y., Yanaga K. Immunogene therapy against colon cancer metastasis using an adenovirus vector expressing CD40 ligand. Surgery 2010, 148:925-935.
164. Imler J.L., Chartier C., Dreyer D., Dieterle A., Sainte-Marie M., Faure T., et al. Novel complementation cell lines derived from human lung carcinoma A549 cells support the growth of E1-deleted adenovirus vectors. Gene Therapy 1996, 3:75-84.
165. Iwata-Kajihara T., Sumimoto H., Kawamura N., Ueda R., Takahashi T., Mizuguchi H., et al. Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors. Journal of Immunology 2011, 187:27-36.
166. Jager L., Hausl M.A., Rauschhuber C., Wolf N.M., Kay M.A., Ehrhardt A. A rapid protocol for construction and production of high-capacity adenoviral vectors. Nature Protocols 2009, 4:547-564.
167. Ji L., Bouvet M., Price R.E., Roth J.A., Fang B. Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement. Gene Therapy 1999, 6:393-402.
168. Jiang Y., Wang M. Personalized medicine in oncology: Tailoring the right drug to the right patient. Biomarkers in Medicine 2010, 4:523-533.
169. Jiang H., White E.J., Ríos-Vicil C.I., Xu J., Gomez-Manzano C., Fueyo J. Human adenovirus type 5 induces cell lysis through autophagy and autophagy-triggered caspase activity. Journal of Virology 2011, 85:4720-4729.
170. Johansson C., Jonsson M., Marttila M., Persson D., Fan X.-L., Skog J., et al. Adenoviruses use lactoferrin as a bridge for CAR-independent binding to and infection of epithelial cells. Journal of Virology 2007, 81:954-963.
171. Johnson D.J.D., Langdown J., Huntington J.A. Molecular basis of factor IXa recognition by heparin-activated antithrombin revealed by a 1.7-A structure of the ternary complex. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:645-650.
172. Jones M.S., Harrach B., Ganac R.D., Gozum M.M.A., Dela Cruz W.P., Riedel B., et al. New adenovirus species found in a patient presenting with gastroenteritis. Journal of Virology 2007, 81:5978-5984.
173. Jongbloed S.L., Kassianos A.J., McDonald K.J., Clark G.J., Ju X., Angel C.E., et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. The Journal of Experimental Medicine 2010, 207:1247-1260.
174. Jonsson M.I., Lenman A.E., Frangsmyr L., Nyberg C., Abdullahi M., Arnberg N. Coagulation factors IX and X enhance binding and infection of adenovirus types 5 and 31 in human epithelial cells. Journal of Virology 2009, 83:3816-3825.
175. Kahl C.A., Bonnell J., Hiriyanna S., Fultz M., Nyberg-Hoffman C., Chen P., et al. Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28. Vaccine 2010, 28:5691-5702.
176. Kaneko H., Aoki K., Ishida S., Ohno S., Kitaichi N., Ishiko H., et al. Recombination analysis of intermediate human adenovirus type 53 in Japan by complete genome sequence. The Journal of General Virology 2011, 92:1251-1259.
177. Kaplan D.H., Shankaran V., Dighe A.S., Stockert E., Aguet M., Old L.J., et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:7556-7561.
178. Kar U.K., Srivastava M.K., Andersson A., Baratelli F., Huang M., Kickhoefer V.A., et al. Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growth. PLoS One 2011, 6:e18758.
179. Karan D., Krieg A.M., Lubaroff D.M. Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine. International Journal of Cancer 2007, 121:1520-1528.
180. Kasaian K., Jones S.J. A new frontier in personalized cancer therapy: Mapping molecular changes. Future Oncology 2011, 7:873-894.
181. Kashentseva E.A., Seki T., Curiel D.T., Dmitriev I.P. Adenovirus targeting to c-erbB-2 oncoprotein by single-chain antibody fused to trimeric form of adenovirus receptor ectodomain. Cancer Research 2002, 62:609-616.
182. Kass E., Panicali D.L., Mazzara G., Schlom J., Greiner J.W. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Research 2001, 61:206-214.
183. Kemper C., Leung M., Stephensen C.B., Pinkert C.A., Liszewski M.K., Cattaneo R., et al. Membrane cofactor protein (MCP; CD46) expression in transgenic mice. Clinical and Experimental Immunology 2001, 124:180-189.
184. Kepp O., Tesniere A., Schlemmer F., Michaud M., Senovilla L., Zitvogel L., et al. Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis 2009, 14:364-375.
185. Khare R., Chen C.Y., Weaver E.A., Barry M.A. Advances and future challenges in adenoviral vector pharmacology and targeting. Current Gene Therapy 2011, 11:241-258.
186. Khare R., Reddy V.S., Nemerow G.R., Barry M.A. Identification of adenovirus serotype 5 hexon regions that interact with scavenger receptors. Journal of Virology 2011, 86:2293-2301.
187. Kibuuka H., Kimutai R., Maboko L., Sawe F., Schunk M.S., Kroidl A., et al. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). The Journal of Infectious Diseases 2010, 201:600-607.
188. Kikuchi T., Crystal R.G. Anti-tumor immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells. Human Gene Therapy 1999, 10:1375-1387.
189. Kikuchi T., Moore M.A., Crystal R.G. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. Blood 2000, 96:91-99.
190. Kim Y.-S., Kim Y.-J., Lee J.-M., Han S.-H., Ko H.-J., Park H.-J., et al. CD40-targeted recombinant adenovirus significantly enhances the efficacy of antitumor vaccines based on dendritic cells and B cells. Human Gene Therapy 2010, 21:1697-1706.
191. Kim Y.-J., Ko H.-J., Kim Y.-S., Kim D.-H., Kang S., Kim J.-M., et al. alpha-Galactosylceramide-loaded, antigen-expressing B cells prime a wide spectrum of antitumor immunity. International Journal of Cancer 2008, 122:2774-2783.
192. Kim J., Smith T., Idamakanti N., Mulgrew K., Kaloss M., Kylefjord H., et al. Targeting adenoviral vectors by using the extracellular domain of the coxsackie-adenovirus receptor: Improved potency via trimerization. Journal of Virology 2002, 76:1892-1903.
193. Kirk C.J., Hartigan-O'Connor D., Mule J.J. The dynamics of the T-cell antitumor response: Chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Research 2001, 61:8794-8802.
194. Kirk C.J., Hartigan-O'Connor D., Nickoloff B.J., Chamberlain J.S., Giedlin M., Aukerman L., et al. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: Augmentation of dendritic cell-based immunotherapy. Cancer Research 2001, 61:2062-2070.
195. Knippertz I., Hesse A., Schunder T., Kämpgen E., Brenner M.K., Schuler G., et al. Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma. Journal of Immunotherapy 2009, 32:524-538.
196. Ko S.-Y., Ko H.-J., Chang W.-S., Park S.-H., Kweon M.-N., Kang C.-Y. alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. Journal of Immunology 2005, 175:3309-3317.
197. Koizumi N., Yamaguchi T., Kawabata K., Sakurai F., Sasaki T., Watanabe Y., et al. Fiber-modified adenovirus vectors decrease liver toxicity through reduced IL-6 production. Journal of Immunology 2007, 178:1767-1773.
198. Korn T., Nettelbeck D.M., Völkel T., Müller R., Kontermann R.E. Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: A comparative analysis of bacterially expressed single-chain diabody and tandem scFv. The Journal of Gene Medicine 2004, 6:642-651.
199. Korokhov N., de Gruijl T.D., Aldrich W.A., Triozzi P.L., Banerjee P.T., Gillies S.D., et al. High efficiency transduction of dendritic cells by adenoviral vectors targeted to DC-SIGN. Cancer Biology & Therapy 2005, 4:289-294.
200. Korokhov N., Mikheeva G., Krendelshchikov A., Belousova N., Simonenko V., Krendelshchikova V., et al. Targeting of adenovirus via genetic modification of the viral capsid combined with a protein bridge. Journal of Virology 2003, 77:12931-12940.
201. Korokhov N., Noureddini S.C., Curiel D.T., Santegoets S.J.A.M., Scheper R.J., de Gruijl T.D. A single-component CD40-targeted adenovirus vector displays highly efficient transduction and activation of dendritic cells in a human skin substrate system. Molecular Pharmaceutics 2005, 2:218-223.
202. Kortylewski M., Kujawski M., Wang T., Wei S., Zhang S., Pilon-Thomas S., et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nature Medicine 2005, 11:1314-1321.
203. Koski A., Kangasniemi L., Escutenaire S., Pesonen S., Cerullo V., Diaconu I., et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Molecular Therapy 2010, 18:1874-1884.
204. Koup R.A., Roederer M., Lamoreaux L., Fischer J., Novik L., Nason M.C., et al. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One 2010, 5:e9015.
205. Krasnykh V., Dmitriev I., Mikheeva G., Miller C.R., Belousova N., Curiel D.T. Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. Journal of Virology 1998, 72:1844-1852.
206. Krasnykh V.N., Douglas J.T., van Beusechem V.W. Genetic targeting of adenoviral vectors. Molecular Therapy 2000, 1:391-405.
207. Krause A., Joh J.H., Hackett N.R., Roelvink P.W., Bruder J.T., Wickham T.J., et al. Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity. Journal of Virology 2006, 80:5523-5530.
208. Kresge K.J. A STEP back? Newspaper article. IAVI Report 2007, 11:1-5.
209. Kuball J., Schuler M., Antunes Ferreira E., Herr W., Neumann M., Obenauer-Kutner L., et al. Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man. Gene Therapy 2002, 9:833-843.
210. Kumamoto T., Huang E.K., Paek H.J., Morita A., Matsue H., Valentini R.F., et al. Induction of tumor-specific protective immunity by in situ Langerhans cell vaccine. Nature Biotechnology 2002, 20:64-69.
211. Lapenta C., Santini S.M., Spada M., Donati S., Urbani F., Accapezzato D., et al. IFN-alpha-conditioned dendritic cells are highly efficient in inducing cross-priming CD8(+) T cells against exogenous viral antigens. European Journal of Immunology 2006, 36:2046-2060.
212. Lapteva N., Aldrich M., Rollins L., Ren W., Goltsova T., Chen S.-Y., et al. Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity. Molecular Therapy 2009, 17:1626-1636.
213. Lapteva N., Aldrich M., Weksberg D., Rollins L., Goltsova T., Chen S.-Y., et al. Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity. Journal of Immunotherapy 2009, 32:145-156.
214. Lasarte J.J., Casares N., Gorraiz M., Hervás-Stubbs S., Arribillaga L., Mansilla C., et al. The extra domain A from fibronectin targets antigens to TLR4-expressing cells and induces cytotoxic T cell responses in vivo. Journal of Immunology 2007, 178:748-756.
215. Ledford H. Melanoma drug wins US approval. Nature 2011, 471:561.
216. Lee Y.-S., Kim J.-H., Choi K.-J., Choi I.-K., Kim H., Cho S., et al. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model. Clinical Cancer Research 2006, 12:5859-5868.
217. Lee C.T., Wu S., Ciernik I.F., Chen H., Nadaf-Rahrov S., Gabrilovich D., et al. Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor. Human Gene Therapy 1997, 8:187-193.
218. Lemckert A.A.C., Sumida S.M., Holterman L., Vogels R., Truitt D.M., Lynch D.M., et al. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-Ad5 immunity. Journal of Virology 2005, 79:9694-9701.
219. Lemke C.D., Graham J.B., Geary S.M., Zamba G., Lubaroff D.M., Salem A.K. Chitosan is a surprising negative modulator of cytotoxic CD8 +T cell responses elicited by adenovirus cancer vaccines. Molecular Pharmaceutics 2011, 8:1652-1661.
220. Li E., Brown S.L., Stupack D.G., Puente X.S., Cheresh D.A., Nemerow G.R. Integrin alpha(v)beta1 is an adenovirus coreceptor. Journal of Virology 2001, 75:5405-5409.
221. Li J.-L., Liu H.-L., Zhang X.-R., Xu J.-P., Hu W.-K., Liang M., et al. A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients. Gene Therapy 2009, 16:376-382.
222. Li Y., Wang L.-X., Yang G., Hao F., Urba W.J., Hu H.-M. Efficient cross-presentation depends on autophagy in tumor cells. Cancer Research 2008, 68:6889-6895.
223. Lindenberg J.J., Fehres C.M., van Cruijsen H., Oosterhoff D., de Gruijl T.D. Cross-talk between tumor and myeloid cells: How to tip the balance in favor of antitumor immunity. Immunotherapy 2011, 3:77-96.
224. Lindsay R.W.B., Darrah P.A., Quinn K.M., Wille-Reece U., Mattei L.M., Iwasaki A., et al. CD8+ T cell responses following replication-defective adenovirus serotype 5 immunization are dependent on CD11c+ dendritic cells but show redundancy in their requirement of TLR and nucleotide-binding oligomerization domain-like receptor signaling. Journal of Immunology 2010, 185:1513-1521.
225. Liu M.A. Immunologic basis of vaccine vectors. Immunity 2010, 33:504-515.
226. Liu X., Cao X., Wei R., Cai Y., Li H., Gui J., et al. Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL. Cancer Gene Therapy 2011, 19:49-57.
227. Liu F., Fang C., Ye X., Lu Q., Yu D.-H., Zhang W.-W., et al. Anti-4-1BB scFv immunogene therapy and low dose cyclophosphamide exhibit a synergistic antitumor effect in established murine lung tumors. Cancer Biology & Therapy 2009, 8:707-713.
228. Liu F., Lu Q., Ye X., Fang C., Zhao Y., Liang M., et al. Cancer gene therapy of adenovirus-mediated anti-4-1BB scFv in immunocompetent mice. Cancer Biology & Therapy 2008, 7:448-453.
229. Lopes L., Dewannieux M., Gileadi U., Bailey R., Ikeda Y., Whittaker C., et al. Immunization with a lentivector that targets tumor antigen expression to dendritic cells induces potent CD8+ and CD4+ T-cell responses. Journal of Virology 2008, 82:86-95.
230. Loré K., Adams W.C., Havenga M.J.E., Precopio M.L., Holterman L., Goudsmit J., et al. Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses. Journal of Immunology 2007, 179:1721-1729.
231. Lotem M., Zhao Y., Riley J., Hwu P., Morgan R.A., Rosenberg S.A., et al. Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors. Journal of Immunotherapy 2006, 29:616-627.
232. Lubaroff D.M., Konety B.R., Link B., Gerstbrein J., Madsen T., Shannon M., et al. Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: Safety and immunologic results. Clinical Cancer Research 2009, 15:7375-7380.
233. Madisch I., Harste G., Pommer H., Heim A. Phylogenetic analysis of the main neutralization and hemagglutination determinants of all human adenovirus prototypes as a basis for molecular classification and taxonomy. Journal of Virology 2005, 79:15265-15276.
234. Magnusson M.K., Kraaij R., Leadley R.M., De Ridder C.M.A., van Weerden W.M., Van Schie K.A.J., et al. A transductionally retargeted adenoviral vector for virotherapy of Her2/neu-expressing prostate cancer. Human Gene Therapy 2012, 23:70-82.
235. Malmström P.-U., Loskog A.S.I., Lindqvist C.A., Mangsbo S.M., Fransson M., Wanders A., et al. AdCD40L immunogene therapy for bladder carcinoma-The first phase I/IIa trial. Clinical Cancer Research 2010, 16:3279-3287.
236. Malvicini M., Ingolotti M., Piccioni F., Garcia M., Bayo J., Atorrasagasti C., et al. Reversal of gastrointestinal carcinoma-induced immunosuppression and induction of antitumoural immunity by a combination of cyclophosphamide and gene transfer of IL-12. Molecular Oncology 2011, 5:242-255.
237. Marshall E. Gene therapy death prompts review of adenovirus vector. Science 1999, 286:2244-2245.
238. Mast T.C., Kierstead L., Gupta S.B., Nikas A.A., Kallas E.G., Novitsky V., et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 2010, 28:950-957.
239. Matthews Q.L. Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach. Molecular Pharmaceutics 2011, 8:3-11.
240. Matthews Q.L., Yang P., Wu Q., Belousova N., Rivera A.A., Stoff-Khalili M.A., et al. Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach. Virology Journal 2008, 5:98.
241. Mazzolini G., Alfaro C., Sangro B., Feijoó E., Ruiz J., Benito A., et al. Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. Journal of Clinical Oncology 2005, 23:999-1010.
242. Mazzolini G., Prieto J., Melero I. Gene therapy of cancer with interleukin-12. Current Pharmaceutical Design 2003, 9:1981-1991.
243. McConnell M.J., Danthinne X., Imperiale M.J. Characterization of a permissive epitope insertion site in adenovirus hexon. Journal of Virology 2006, 80:5361-5370.
244. McCoy K., Tatsis N., Korioth-Schmitz B., Lasaro M.O., Hensley S.E., Lin S.-W., et al. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. Journal of Virology 2007, 81:6594-6604.
245. McGuire K.A., Barlan A.U., Griffin T.M., Wiethoff C.M. Adenovirus type 5 rupture of lysosomes leads to cathepsin B-dependent mitochondrial stress and production of reactive oxygen species. Journal of Virology 2011, 85:10806-10813.
246. Melief C.J.M., van Der Burg S.H., Toes R.E.M., Ossendorp F., Offringa R. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunological Reviews 2002, 188:177-182.
247. Merad M., Manz M.G. Dendritic cell homeostasis. Blood 2009, 113:3418-3427.
248. Mescher M.F., Curtsinger J.M., Agarwal P., Casey K.A., Gerner M., Hammerbeck C.D., et al. Signals required for programming effector and memory development by CD8+ T cells. Immunological Reviews 2006, 211:81-92.
249. Miller G., Lahrs S., Pillarisetty V.G., Shah A.B., DeMatteo R.P. Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated tumor protection. Cancer Research 2002, 62:5260-5266.
250. Mincheff M., Tchakarov S., Zoubak S., Loukinov D., Botev C., Altankova I., et al. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: A phase I/II clinical trial. European Urology 2000, 38:208-217.
251. Mizuguchi H., Kay M.A., Hayakawa T. Approaches for generating recombinant adenovirus vectors. Advanced Drug Delivery Reviews 2001, 52:165-176.
252. Mok H., Palmer D., Ng P., Barry M. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Molecular Therapy 2005, 11:66-79.
253. Molinier-Frenkel V., Lengagne R., Gaden F., Hong S.-S., Choppin J., Gahery-Ségard H., et al. Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. Journal of Virology 2002, 76:127-135.
254. Morita A., Ariizumi K., Ritter R., Jester J.V., Kumamoto T., Johnston S.A., et al. Development of a Langerhans cell-targeted gene therapy format using a dendritic cell-specific promoter. Gene Therapy 2001, 8:1729-1737.
255. Muruve D.A., Cotter M.J., Zaiss A.K., White L.R., Liu Q., Chan T., et al. Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. Journal of Virology 2004, 78:5966-5972.
256. Nefedova Y., Fishman M., Sherman S., Wang X., Beg A.A., Gabrilovich D.I. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Research 2007, 67:11021-11028.
257. Nefedova Y., Huang M., Kusmartsev S., Bhattacharya R., Cheng P., Salup R., et al. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. Journal of Immunology 2004, 172:464-474.
258. Nefedova Y., Nagaraj S., Rosenbauer A., Muro-Cacho C., Sebti S.M., Gabrilovich D.I. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Research 2005, 65:9525-9535.
259. Nemerow G.R., Pache L., Reddy V., Stewart P.L. Insights into adenovirus host cell interactions from structural studies. Virology 2009, 384:380-388.
260. Nemunaitis J., Meyers T., Senzer N., Cunningham C., West H., Vallieres E., et al. Phase I trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer. Molecular Therapy 2006, 13:1185-1191.
261. Nettelbeck D.M., Miller D.W., Jérôme V., Zuzarte M., Watkins S.J., Hawkins R.E., et al. Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105). Molecular Therapy 2001, 3:882-891.
262. Nettelbeck D.M., Rivera A.A., Kupsch J., Dieckmann D., Douglas J.T., Kontermann R.E., et al. Retargeting of adenoviral infection to melanoma: Combining genetic ablation of native tropism with a recombinant bispecific single-chain diabody (scDb) adapter that binds to fiber knob and HMWMAA. International Journal of Cancer 2004, 108:136-145.
263. Ni S., Bernt K., Gaggar A., Li Z.-Y., Kiem H.-P., Lieber A. Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons. Human Gene Therapy 2005, 16:664-677.
264. Nicklin S.A., Wu E., Nemerow G.R., Baker A.H. The influence of adenovirus fiber structure and function on vector development for gene therapy. Molecular Therapy 2005, 12:384-393.
265. Nociari M., Ocheretina O., Schoggins J.W., Falck-Pedersen E. Sensing infection by adenovirus: Toll-like receptor-independent viral DNA recognition signals activation of the interferon regulatory factor 3 master regulator. Journal of Virology 2007, 81:4145-4157.
266. Ogawara K.-I., Rots M.G., Kok R.J., Moorlag H.E., Van Loenen A.-M., Meijer D.K.F., et al. A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. Human Gene Therapy 2004, 15:433-443.
267. Ojima T., Iwahashi M., Nakamura M., Matsuda K., Nakamori M., Ueda K., et al. Benefits of gene transduction of granulocyte macrophage colony-stimulating factor in cancer vaccine using genetically modified dendritic cells. International Journal of Oncology 2007, 31:931-939.
268. Okada N., Sasaki A., Niwa M., Okada Y., Hatanaka Y., Tani Y., et al. Tumor suppressive efficacy through augmentation of tumor-infiltrating immune cells by intratumoral injection of chemokine-expressing adenoviral vector. Cancer Gene Therapy 2006, 13:393-405.
269. Olive M., Eisenlohr L., Flomenberg N., Hsu S., Flomenberg P. The adenovirus capsid protein hexon contains a highly conserved human CD4+ T-cell epitope. Human Gene Therapy 2002, 13:1167-1178.
270. Oosterhoff D., Sluijter B.J.R., Hangalapura B.N., de Gruijl T.D. The dermis as a portal for dendritic cell-targeted immunotherapy of cutaneous melanoma. Current Topics in Microbiology and Immunology 2012, 351:181-220.
271. Ophorst O.J.A.E., Kostense S., Goudsmit J., de Swart R.L., Verhaagh S., Zakhartchouk A., et al. An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity. Vaccine 2004, 22:3035-3044.
272. Ophorst O.J.A.E., Radosevic K., Klap J.M., Sijtsma J., Gillissen G., Mintardjo R., et al. Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant. Vaccine 2007, 25:6501-6510.
273. O'Riordan C.R., Lachapelle A., Delgado C., Parkes V., Wadsworth S.C., Smith A.E., et al. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Human Gene Therapy 1999, 10:1349-1358.
274. Othman M., Labelle A., Mazzetti I., Elbatarny H.S., Lillicrap D. Adenovirus-induced thrombocytopenia: The role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance. Blood 2007, 109:2832-2839.
275. Palm N.W., Medzhitov R. Pattern recognition receptors and control of adaptive immunity. Immunological Reviews 2009, 227:221-233.
276. Palucka K., Ueno H., Fay J., Banchereau J. Harnessing dendritic cells to generate cancer vaccines. Annals of the New York Academy of Sciences 2009, 1174:88-98.
277. Paoloni M., Khanna C. Translation of new cancer treatments from pet dogs to humans. Nature Reviews. Cancer 2008, 8:147-156.
278. Park K.-H., Kim G., Jang S.H., Kim C.H., Kwon S.-Y., Yoo C.-G., et al. Gene therapy with GM-CSF, interleukin-4 and herpes simplex virus thymidine kinase shows strong antitumor effect on lung cancer. Anticancer Research 2003, 23:1559-1564.
279. Park J.W., Mok H., Park T.G. Epidermal growth factor (EGF) receptor targeted delivery of PEGylated adenovirus. Biochemical and Biophysical Research Communications 2008, 366:769-774.
280. Parks R. Adenovirus protein IX: A new look at an old protein. Molecular Therapy 2005, 11:19-25.
281. Patterson L.J. The " STEP-wise" future of adenovirus-based HIV vaccines. Current Medicinal Chemistry 2011, 18:3981-3986.
282. Pereboev A.V., Asiedu C.K., Kawakami Y., Dong S.S., Blackwell J.L., Kashentseva E.A., et al. Coxsackievirus-adenovirus receptor genetically fused to anti-human CD40 scFv enhances adenoviral transduction of dendritic cells. Gene Therapy 2002, 9:1189-1193.
283. Pereboeva L., Komarova S., Roth J., Ponnazhagan S., Curiel D.T. Targeting EGFR with metabolically biotinylated fiber-mosaic adenovirus. Gene Therapy 2007, 14:627-637.
284. Perkins S.D., Williams A.J., O'Brien L.M., Laws T.R., Phillpotts R.J. CpG used as an adjuvant for an adenovirus-based Venezuelan equine encephalitis virus vaccine increases the immune response to the vector, but not to the transgene product. Viral Immunology 2008, 21:451-457.
285. Pesonen S., Diaconu I., Cerullo V., Escutenaire S., Raki M., Kangasniemi L., et al. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. International Journal of Cancer 2012, 130:1937-1947.
286. Pesonen S., Diaconu I., Kangasniemi L., Ranki T., Kanerva A., Pesonen S.K., et al. Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: Assessment of safety and immunologic responses in patients. Cancer Research 2012, 72:1621-1631.
287. Pincha M., Sundarasetty B.S., Stripecke R. Lentiviral vectors for immunization: An inflammatory field. Expert Review of Vaccines 2010, 9:309-321.
288. Pooley J.L., Heath W.R., Shortman K. Cutting edge: Intravenous soluble antigen is presented to CD4 T cells by CD8- dendritic cells, but cross-presented to CD8 T cells by CD8+ dendritic cells. Journal of Immunology 2001, 166:5327-5330.
289. Porgador A., Irvine K.R., Iwasaki A., Barber B.H., Restifo N.P., Germain R.N. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. The Journal of Experimental Medicine 1998, 188:1075-1082.
290. Poschke I., Mougiakakos D., Hansson J., Masucci G.V., Kiessling R. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Research 2010, 70:4335-4345.
291. Poulin L.F., Salio M., Griessinger E., Anjos-Afonso F., Craciun L., Chen J.-L., et al. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. The Journal of Experimental Medicine 2010, 207:1261-1271.
292. Radosevic K., Rodríguez A., Lemckert A.A.C., van der Meer M., Gillissen G., Warnar C., et al. The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert. Clinical and Vaccine Immunology 2010, 17:1687-1694.
293. Raki M., Sarkioja M., Escutenaire S., Kangasniemi L., Haavisto E., Kanerva A., et al. Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients. The Journal of Gene Medicine 2011, 13:253-261.
294. Rea D., Havenga M.J., van Den Assem M., Sutmuller R.P., Lemckert A., Hoeben R.C., et al. Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. Journal of Immunology 2001, 166:5236-5244.
295. Rea D., Schagen F.H., Hoeben R.C., Mehtali M., Havenga M.J., Toes R.E., et al. Adenoviruses activate human dendritic cells without polarization toward a T-helper type 1-inducing subset. Journal of Virology 1999, 73:10245-10253.
296. Rhee E.G., Blattman J.N., Kasturi S.P., Kelley R.P., Kaufman D.R., Lynch D.M., et al. Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors. Journal of Virology 2010, 85:315-323.
297. Ribas A., Butterfield L.H., McBride W.H., Dissette V.B., Koh A., Vollmer C.M., et al. Characterization of antitumor immunization to a defined melanoma antigen using genetically engineered murine dendritic cells. Cancer Gene Therapy 1999, 6:523-536.
298. Ribas A., Butterfield L.H., McBride W.H., Jilani S.M., Bui L.A., Vollmer C.M., et al. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cancer Research 1997, 57:2865-2869.
299. Ridge J.P., Di Rosa F., Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998, 393:474-478.
300. Rieger R., Kipps T.J. CpG oligodeoxynucleotides enhance the capacity of adenovirus-mediated CD154 gene transfer to generate effective B-cell lymphoma vaccines. Cancer Research 2003, 63:4128-4135.
301. Rizza P., Capone I., Moretti F., Proietti E., Belardelli F. IFN-α as a vaccine adjuvant: Recent insights into the mechanisms and perspectives for its clinical use. Expert Review of Vaccines 2011, 10:487-498.
302. Robert-Guroff M. Replicating and non-replicating viral vectors for vaccine development. Current Opinion in Biotechnology 2007, 18:546-556.
303. Roberts D.M., Nanda A., Havenga M.J.E., Abbink P., Lynch D.M., Ewald B.A., et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 2006, 441:239-243.
304. Robinson M., Li B., Ge Y., Ko D., Yendluri S., Harding T., et al. Novel immunocompetent murine tumor model for evaluation of conditionally replication-competent (oncolytic) murine adenoviral vectors. Journal of Virology 2009, 83:3450-3462.
305. Rodríguez A., Mintardjo R., Tax D., Gillissen G., Custers J., Pau M.G., et al. Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys. Vaccine 2009, 27:6226-6233.
306. Rodriguez-Rocha H., Gomez-Gutierrez J.G., Garcia-Garcia A., Rao X.-M., Chen L., McMasters K.M., et al. Adenoviruses induce autophagy to promote virus replication and oncolysis. Virology 2011, 416:9-15.
307. Roelvink P.W., Kovesdi I., Wickham T.J. Comparative analysis of adenovirus fiber-cell interaction: Adenovirus type 2 (Ad2) and Ad9 utilize the same cellular fiber receptor but use different binding strategies for attachment. Journal of Virology 1996, 70:7614-7621.
308. Roelvink P.W., Lizonova A., Lee J.G., Li Y., Bergelson J.M., Finberg R.W., et al. The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. Journal of Virology 1998, 72:7909-7915.
309. Roelvink P.W., Mi Lee G., Einfeld D.A., Kovesdi I., Wickham T.J. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. Science 1999, 286:1568-1571.
310. Rollier C.S., Reyes-Sandoval A., Cottingham M.G., Ewer K., Hill A.V.S. Viral vectors as vaccine platforms: Deployment in sight. Current Opinion in Immunology 2011, 23:377-382.
311. Romani N., Clausen B.E., Stoitzner P. Langerhans cells and more: Langerin-expressing dendritic cell subsets in the skin. Immunological Reviews 2010, 234:120-141.
312. Rosa D.S., Ribeiro S.P., Cunha-Neto E. CD4+ T cell epitope discovery and rational vaccine design. Archivum Immunologiae et Therapiae Experimentalis 2010, 58:121-130.
313. Rosario M., Borthwick N., Stewart-Jones G.B., Mbewe-Mvula A., Bridgeman A., Colloca S., et al. Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques. AIDS 2012, 26:275-284.
314. Rosenberg S.A., Zhai Y., Yang J.C., Schwartzentruber D.J., Hwu P., Marincola F.M., et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. Journal of the National Cancer Institute 1998, 90:1894-1900.
315. Roy S., Shirley P.S., McClelland A., Kaleko M. Circumvention of immunity to the adenovirus major coat protein hexon. Journal of Virology 1998, 72:6875-6879.
316. Russell W.C. Adenoviruses: Update on structure and function. The Journal of General Virology 2009, 90:1-20.
317. Sakurai F., Kawabata K., Mizuguchi H. Adenovirus vectors composed of subgroup B adenoviruses. Current Gene Therapy 2007, 7:229-238.
318. Sangro B., Mazzolini G., Ruiz J., Herraiz M., Quiroga J., Herrero I., et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. Journal of Clinical Oncology 2004, 22:1389-1397.
319. Sarkar D., Lebedeva I.V., Su Z.Z., Park E.S., Chatman L., Vozhilla N., et al. Eradication of therapy-resistant human prostate tumors using a cancer terminator virus. Cancer Research 2007, 67:5434-5442.
320. Sarkar D., Su Z.Z., Park E.S., Vozhilla N., Dent P., Curiel D.T., et al. A cancer terminator virus eradicates both primary and distant human melanomas. Cancer Gene Therapy 2008, 15:293-302.
321. Sarkar D., Su Z.Z., Vozhilla N., Park E.S., Gupta P., Fisher P.B. Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:14034-14039.
322. Sarkar D., Su Z.Z., Vozhilla N., Park E.S., Randolph A., Valerie K., et al. Targeted virus replication plus immunotherapy eradicates primary and distant pancreatic tumors in nude mice. Cancer Research 2005, 65:9056-9063.
323. Sas S., Chan T., Sami A., El-Gayed A., Xiang J. Vaccination of fiber-modified adenovirus-transfected dendritic cells to express HER-2/neu stimulates efficient HER-2/neu-specific humoral and CTL responses and reduces breast carcinogenesis in transgenic mice. Cancer Gene Therapy 2008, 15:655-666.
324. Satoh T., Saika T., Ebara S., Kusaka N., Timme T.L., Yang G., et al. Macrophages transduced with an adenoviral vector expressing interleukin 12 suppress tumor growth and metastasis in a preclinical metastatic prostate cancer model. Cancer Research 2003, 63:7853-7860.
325. Sauane M., Su Z.Z., Gupta P., Lebedeva I.V., Dent P., Sarkar D., et al. Autocrine regulation of mda-7/IL-24 mediates cancer-specific apoptosis. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:9763-9768.
326. Schierer S., Hesse A., Knippertz I., Kaempgen E., Baur A.S., Schuler G., et al. Human dendritic cells efficiently phagocytose adenoviral oncolysate but require additional stimulation to mature. International Journal of Cancer 2012, 130:1682-1694.
327. Schierer S., Hesse A., Müller I., Kämpgen E., Curiel D.T., Schuler G., et al. Modulation of viability and maturation of human monocyte-derived dendritic cells by oncolytic adenoviruses. International Journal of Cancer 2007, 122:219-229.
328. Schirmbeck R., Reimann J., Kochanek S., Kreppel F. The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens. Molecular Therapy 2008, 16:1609-1616.
329. Schoenberger S.P., Toes R.E., van der Voort E.I., Offringa R., Melief C.J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998, 393:480-483.
330. Schowalter D.B., Tubb J.C., Liu M., Wilson C.B., Kay M.A. Heterologous expression of adenovirus E3-gp19K in an E1a-deleted adenovirus vector inhibits MHC I expression in vitro, but does not prolong transgene expression in vivo. Gene Therapy 1997, 4:351-360.
331. Segerman A., Atkinson J.P., Marttila M., Dennerquist V., Wadell G., Arnberg N. Adenovirus type 11 uses CD46 as a cellular receptor. Journal of Virology 2003, 77:9183-9191.
332. Segerman A., Lindman K., Mei Y.-F., Allard A., Wadell G. Adenovirus types 11p and 35 attach to and infect primary lymphocytes and monocytes, but hexon expression in T-cells requires prior activation. Virology 2006, 349:96-111.
333. Seiler M.P., Cerullo V., Lee B. Immune response to helper dependent adenoviral mediated liver gene therapy: Challenges and prospects. Current Gene Therapy 2007, 7:297-305.
334. Seiradake E., Henaff D., Wodrich H., Billet O., Perreau M., Hippert C., et al. The cell adhesion molecule " CAR" and sialic acid on human erythrocytes influence adenovirus in vivo biodistribution. PLoS Pathogens 2009, 5:e1000277.
335. Sekaly R.-P. The failed HIV Merck vaccine study: A step back or a launching point for future vaccine development?. The Journal of Experimental Medicine 2008, 205:7-12.
336. Seregin S.S., Amalfitano A. Improving adenovirus based gene transfer: Strategies to accomplish immune evasion. Viruses 2010, 2:2013-2036.
337. Seshidhar Reddy P., Ganesh S., Limbach M.P., Brann T., Pinkstaff A., Kaloss M., et al. Development of adenovirus serotype 35 as a gene transfer vector. Virology 2003, 311:384-393.
338. Seto D., Chodosh J., Brister J.R., Jones M.S. Using the whole-genome sequence to characterize and name human adenoviruses. Journal of Virology 2011, 85:5701-5702. Members of the Adenovirus Research Community.
339. Seya T., Hirano A., Matsumoto M., Nomura M., Ueda S. Human membrane cofactor protein (MCP, CD46): Multiple isoforms and functions. The International Journal of Biochemistry & Cell Biology 1999, 31:1255-1260.
340. Seya T., Nomura M., Murakami Y., Begum N.A., Matsumoto M., Nagasawa S. CD46 (membrane cofactor protein of complement, measles virus receptor): Structural and functional divergence among species (review). International Journal of Molecular Medicine 1998, 1:809-816.
341. Sheehy S.H., Duncan C.J., Elias S.C., Collins K.A., Ewer K.J., Spencer A.J., et al. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Molecular Therapy 2011, 19:2269-2276.
342. Shimony N., Elkin G., Kolodkin-Gal D., Krasny L., Urieli-Shoval S., Haviv Y.S. Analysis of adenoviral attachment to human platelets. Virology Journal 2009, 6:25.
343. Shiver J.W., Fu T.-M., Chen L., Casimiro D.R., Davies M.-E., Evans R.K., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002, 415:331-335.
344. Short J. Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors. Virology 2004, 322:349-359.
345. Short J.J., Vasu C., Holterman M.J., Curiel D.T., Pereboev A. Members of adenovirus species B utilize CD80 and CD86 as cellular attachment receptors. Virus Research 2006, 122:144-153.
346. Simmons A.D., Moskalenko M., Creson J., Fang J., Yi S., VanRoey M.J., et al. Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity. Cancer Immunology, Immunotherapy 2008, 57:1263-1270.
347. Sirena D., Lilienfeld B., Eisenhut M., Kälin S., Boucke K., Beerli R.R., et al. The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. Journal of Virology 2004, 78:4454-4462.
348. Sloan J.M., Kershaw M.H., Touloukian C.E., Lapointe R., Robbins P.F., Restifo N.P., et al. MHC class I and class II presentation of tumor antigen in retrovirally and adenovirally transduced dendritic cells. Cancer Gene Therapy 2002, 9:946-950.
349. Small E.J., Tchekmedyian N.S., Rini B.I., Fong L., Lowy I., Allison J.P. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clinical Cancer Research 2007, 13:1810-1815.
350. Smith J.G., Wiethoff C.M., Stewart P.L., Nemerow G.R. Adenovirus. Current Topics in Microbiology and Immunology 2010, 343:195-224.
351. Smithgall T.E., Briggs S.D., Schreiner S., Lerner E.C., Cheng H., Wilson M.B. Control of myeloid differentiation and survival by Stats. Oncogene 2000, 19:2612-2618.
352. Smyth M.J., Thia K.Y., Street S.E., MacGregor D., Godfrey D.I., Trapani J.A. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. The Journal of Experimental Medicine 2000, 192:755-760.
353. Song M.-Y., Park S.-H., Nam H.J., Choi D.-H., Sung Y.-C. Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1. Journal of Immunotherapy 2011, 34:297-306.
354. Sorensen M.R., Holst P.J., Pircher H., Christensen J.P., Thomsen A.R. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control. European Journal of Immunology 2009, 39:2725-2736.
355. Sorensen M.R., Holst P.J., Steffensen M.A., Christensen J.P., Thomsen A.R. Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model. Vaccine 2010, 28:6757-6764.
356. Steinman R.M. Dendritic cells in vivo: A key target for a new vaccine science. Immunity 2008, 29:319-324.
357. Steitz J., Brück J., Steinbrink K., Enk A., Knop J., Tuting T. Genetic immunization of mice with human tyrosinase-related protein 2: Implications for the immunotherapy of melanoma. International Journal of Cancer 2000, 86:89-94.
358. Steitz J., Tormo D., Schweichel D., Tuting T. Comparison of recombinant adenovirus and synthetic peptide for DC-based melanoma vaccination. Cancer Gene Therapy 2006, 13:318-325.
359. Sterman D.H., Recio A., Haas A.R., Vachani A., Katz S.I., Gillespie C.T., et al. A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. Molecular Therapy 2010, 18:852-860.
360. Stoff-Khalili M.A., Rivera A.A., Glasgow J.N., Le L.P., Stoff A., Everts M., et al. A human adenoviral vector with a chimeric fiber from canine adenovirus type 1 results in novel expanded tropism for cancer gene therapy. Gene Therapy 2005, 12:1696-1706.
361. Stone D., Ni S., Li Z.-Y., Gaggar A., DiPaolo N., Feng Q., et al. Development and assessment of human adenovirus type 11 as a gene transfer vector. Journal of Virology 2005, 79:5090-5104.
362. Sudowe S., Ludwig-Portugall I., Montermann E., Ross R., Reske-Kunz A.B. Transcriptional targeting of dendritic cells in gene gun-mediated DNA immunization favors the induction of type 1 immune responses. Molecular Therapy 2003, 8:567-575.
363. Sumida S.M., Truitt D.M., Lemckert A.A.C., Vogels R., Custers J.H.H.V., Addo M.M., et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. Journal of Immunology 2005, 174:7179-7185.
364. Sutherland R.M., Londrigan S.L., Brady J.L., Azher H., Carrington E.M., Zhan Y., et al. Shutdown of immunological priming and presentation after in vivo administration of adenovirus. Gene Therapy 2011, (Epub ahead of print). 10.1038/gt.2011.187.
365. Tacken P.J., Figdor C.G. Targeted antigen delivery and activation of dendritic cells in vivo: Steps towards cost effective vaccines. Seminars in Immunology 2011, 23:12-20.
366. Tacken P.J., Zeelenberg I.S., Cruz L.J., van Hout-Kuijer M.A., van de Glind G., Fokkink R.G., et al. Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood 2011, 118:6836-6844.
367. Tallone T., Malin S., Samuelsson A., Wilbertz J., Miyahara M., Okamoto K., et al. A mouse model for adenovirus gene delivery. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:7910-7915.
368. Tang J., Olive M., Champagne K., Flomenberg N., Eisenlohr L., Hsu S., et al. Adenovirus hexon T-cell epitope is recognized by most adults and is restricted by HLA DP4, the most common class II allele. Gene Therapy 2004, 11:1408-1415.
369. Tang J., Olive M., Pulmanausahakul R., Schnell M., Flomenberg N., Eisenlohr L., et al. Human CD8+ cytotoxic T cell responses to adenovirus capsid proteins. Virology 2006, 350:312-322.
370. Tatsis N., Blejer A., Lasaro M.O., Hensley S.E., Cun A., Tesema L., et al. A CD46-binding chimpanzee adenovirus vector as a vaccine carrier. Molecular Therapy 2007, 15:608-617.
371. Tatsis N., Lasaro M.O., Lin S.-W., Haut L.H., Xiang Z.Q., Zhou D., et al. Adenovirus vector-induced immune responses in nonhuman primates: Responses to prime boost regimens. Journal of Immunology 2009, 182:6587-6599.
372. Tatsis N., Tesema L., Robinson E.R., Giles-Davis W., McCoy K., Gao G.P., et al. Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Therapy 2006, 13:421-429.
373. Tatsumi T., Takehara T., Yamaguchi S., Sasakawa A., Miyagi T., Jinushi M., et al. Injection of IL-12 gene-transduced dendritic cells into mouse liver tumor lesions activates both innate and acquired immunity. Gene Therapy 2007, 14:863-871.
374. Tenbusch M., Kuate S., Tippler B., Gerlach N., Schimmer S., Dittmer U., et al. Coexpression of GM-CSF and antigen in DNA prime-adenoviral vector boost immunization enhances polyfunctional CD8+ T cell responses, whereas expression of GM-CSF antigen fusion protein induces autoimmunity. BMC Immunology 2008, 9:13.
375. Terme M., Ullrich E., Delahaye N.F., Chaput N., Zitvogel L. Natural killer cell-directed therapies: Moving from unexpected results to successful strategies. Nature Immunology 2008, 9:486-494.
376. Tesniere A., Panaretakis T., Kepp O., Apetoh L., Ghiringhelli F., Zitvogel L., et al. Molecular characteristics of immunogenic cancer cell death. Cell Death and Differentiation 2008, 15:3-12.
377. Thaci B., Ulasov I.V., Wainwright D.A., Lesniak M.S. The challenge for gene therapy: Innate immune response to adenoviruses. Oncotarget 2011, 2:113-121.
378. Thacker E.E., Nakayama M., Smith B.F., Bird R.C., Muminova Z., Strong T.V., et al. A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo. Vaccine 2009, 27:7116-7124.
379. Thorner A.R., Lemckert A.A.C., Goudsmit J., Lynch D.M., Ewald B.A., Denholtz M., et al. Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity. Journal of Virology 2006, 80:12009-12016.
380. Tian S., Liu Z., Donahue C., Falo L.D., You Z. Genetic targeting of the active transcription factor XBP1s to dendritic cells potentiates vaccine-induced prophylactic and therapeutic antitumor immunity. Molecular Therapy 2011, 20:432-442.
381. Tian S., Liu Z., Donahue C., Noh H.S., Falo L.D., You Z. Transcriptional IL-15-directed in vivo DC targeting DNA vaccine. Gene Therapy 2009, 16:1260-1270.
382. Tillman B.W., de Gruijl T.D., Luykx-de Bakker S.A., Scheper R.J., Pinedo H.M., Curiel T.J., et al. Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. Journal of Immunology 1999, 162:6378-6383.
383. Todorova K., Ignatova I., Tchakarov S., Altankova I., Zoubak S., Kyurkchiev S., et al. Humoral immune response in prostate cancer patients after immunization with gene-based vaccines that encode for a protein that is proteasomally degraded. Cancer Immunity 2005, 5:1.
384. Toka F.N., Gieryńska M., Suvas S., Schoenberger S.P., Rouse B.T. Rescue of memory CD8+ T cell reactivity in peptide/TLR9 ligand immunization by codelivery of cytokines or CD40 ligation. Virology 2005, 331:151-158.
385. Tomihara K., Kato K., Masuta Y., Nakamura K., Uchida H., Sasaki K., et al. Gene transfer of CD40-ligand to dendritic cells stimulates interferon-γ production to induce growth arrest and apoptosis of tumor cells. Gene Therapy 2007, 15:203-213.
386. Tomko R.P., Xu R., Philipson L. HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:3352-3356.
387. Toth K., Wold W.S.M. Increasing the efficacy of oncolytic adenovirus vectors. Viruses 2010, 2:1844-1866.
388. Trudel S., Trachtenberg J., Toi A., Sweet J., Li Z.H., Jewett M., et al. A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. Cancer Gene Therapy 2003, 10:755-763.
389. Tsao H., Millman P., Linette G.P., Hodi F.S., Sober A.J., Goldberg M.A., et al. Hypopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanoma. Archives of Dermatology 2002, 138:799-802.
390. Tsujimura A., Shida K., Kitamura M., Nomura M., Takeda J., Tanaka H., et al. Molecular cloning of a murine homologue of membrane cofactor protein (CD46): Preferential expression in testicular germ cells. The Biochemical Journal 1998, 330(Pt. 1):163-168.
391. Tuettenberg A., Jonuleit H., Tuting T., Brück J., Knop J., Enk A.H. Priming of T cells with Ad-transduced DC followed by expansion with peptide-pulsed DC significantly enhances the induction of tumor-specific CD8+ T cells: Implications for an efficient vaccination strategy. Gene Therapy 2003, 10:243-250.
392. Tuting T., Steitz J., Brück J., Gambotto A., Steinbrink K., DeLeo A.B., et al. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity. The Journal of Gene Medicine 1999, 1:400-406.
393. Tuve S., Chen B.-M., Liu Y., Cheng T.-L., Touré P., Sow P.S., et al. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Research 2007, 67:5929-5939.
394. Tuve S., Liu Y., Tragoolpua K., Jacobs J.D., Yumul R.C., Li Z.-Y., et al. In situ adenovirus vaccination engages T effector cells against cancer. Vaccine 2009, 27:4225-4239.
395. Tuve S., Wang H., Jacobs J.D., Yumul R.C., Smith D.F., Lieber A. Role of cellular heparan sulfate proteoglycans in infection of human adenovirus serotype 3 and 35. PLoS Pathogens 2008, 4:e1000189.
396. Ueno H., Palucka A.K., Banchereau J. The expanding family of dendritic cell subsets. Nature Biotechnology 2010, 28:813-815.
397. van Beusechem V.W., Grill J., Mastenbroek D.C.J., Wickham T.J., Roelvink P.W., Haisma H.J., et al. Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished. Journal of Virology 2002, 76:2753-2762.
398. van Cruijsen H., van der Veldt A.A.M., Vroling L., Oosterhoff D., Broxterman H.J., Scheper R.J., et al. Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clinical Cancer Research 2008, 14:5884-5892.
399. van de Ven R., Lindenberg J.J., Oosterhoff D., van den Tol M.P., Rosalia R.A., Murakami M., et al. Selective transduction of mature DC in human skin and lymph nodes by CD80/CD86-targeted fiber-modified adenovirus-5/3. Journal of Immunotherapy 2009, 32:895-906.
400. van de Ven R., Scheffer G.L., Reurs A.W., Lindenberg J.J., Oerlemans R., Jansen G., et al. A role for multidrug resistance protein 4 (MRP4; ABCC4) in human dendritic cell migration. Blood 2008, 112:2353-2359.
401. Vardouli L., Lindqvist C., Vlahou K., Loskog A.S.I., Eliopoulos A.G. Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas. Cancer Gene Therapy 2009, 16:848-860.
402. Verhaagh S., de Jong E., Goudsmit J., Lecollinet S., Gillissen G., de Vries M., et al. Human CD46-transgenic mice in studies involving replication-incompetent adenoviral type 35 vectors. The Journal of General Virology 2006, 87:255-265.
403. Vesely M.D., Kershaw M.H., Schreiber R.D., Smyth M.J. Natural innate and adaptive immunity to cancer. Annual Review of Immunology 2011, 29:235-271.
404. Vigne E., Mahfouz I., Dedieu J.F., Brie A., Perricaudet M., Yeh P. RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. Journal of Virology 1999, 73:5156-5161.
405. Villadangos J.A., Shortman K. Found in translation: The human equivalent of mouse CD8+ dendritic cells. The Journal of Experimental Medicine 2010, 207:1131-1134.
406. von Bubnoff A. Phase I trial of adenovirus-based prime-boost regimen begins in Boston. IAVI Report 2010, 14:18-19.
407. Vonderheide R.H., Flaherty K.T., Khalil M., Stumacher M.S., Bajor D.L., Hutnick N.A., et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. Journal of Clinical Oncology 2007, 25:876-883.
408. Vuylsteke R.J.C.L.M., Molenkamp B.G., Gietema H.A., van Leeuwen P.A.M., Wijnands P.G.J.T.B., Vos W., et al. Local administration of granulocyte/macrophage colony-stimulating factor increases the number and activation state of dendritic cells in the sentinel lymph node of early-stage melanoma. Cancer Research 2004, 64:8456-8460.
409. Vuylsteke R.J.C.L.M., Molenkamp B.G., van Leeuwen P.A.M., Meijer S., Wijnands P.G.J.T.B., Haanen J.B.A.G., et al. Tumor-specific CD8+ T cell reactivity in the sentinel lymph node of GM-CSF-treated stage I melanoma patients is associated with high myeloid dendritic cell content. Clinical Cancer Research 2006, 12:2826-2833.
410. Waddington S.N., McVey J.H., Bhella D., Parker A.L., Barker K., Atoda H., et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008, 132:397-409.
411. Waller E.K. The role of sargramostim (rhGM-CSF) as immunotherapy. The Oncologist 2007, 12(Suppl 2):22-26.
412. Walsh M.P., Seto J., Liu E.B., Dehghan S., Hudson N.R., Lukashev A.N., et al. Computational analysis of two species C human adenoviruses provides evidence of a novel virus. Journal of Clinical Microbiology 2011, 49:3482-3490.
413. Wang W., Edington H.D., Rao U.N.M., Jukic D.M., Land S.R., Ferrone S., et al. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clinical Cancer Research 2007, 13:1523-1531.
414. Wang K., Huang S., Kapoor-Munshi A., Nemerow G. Adenovirus internalization and infection require dynamin. Journal of Virology 1998, 72:3455-3458.
415. Wang H., Li Z.-Y., Liu Y., Persson J., Beyer I., Möller T., et al. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nature Medicine 2011, 17:96-104.
416. Wang T., Niu G., Kortylewski M., Burdelya L., Shain K., Zhang S., et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nature Medicine 2004, 10:48-54.
417. Wang L., Qi X., Sun Y., Liang L., Ju D. Adenovirus-mediated combined P16 gene and GM-CSF gene therapy for the treatment of established tumor and induction of antitumor immunity. Cancer Gene Therapy 2002, 9:819-824.
418. Wargo J.A., Schumacher L.Y., Comin-Anduix B., Dissette V.B., Glaspy J.A., McBride W.H., et al. Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells. Cancer Gene Therapy 2005, 12:516-527.
419. Weber J. Ipilimumab: Controversies in its development, utility and autoimmune adverse events. Cancer Immunology, Immunotherapy 2009, 58:823-830.
420. Weber J. Immune checkpoint proteins: A new therapeutic paradigm for cancer-Preclinical background: CTLA-4 and PD-1 blockade. Seminars in Oncology 2010, 37:430-439.
421. Wickham T.J. Targeting adenovirus. Gene Therapy 2000, 7:110-114.
422. Wickham T.J., Mathias P., Cheresh D.A., Nemerow G.R. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993, 73:309-319.
423. Wickham T.J., Tzeng E., Shears L.L., Roelvink P.W., Li Y., Lee G.M., et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. Journal of Virology 1997, 71:8221-8229.
424. Worgall S., Busch A., Rivara M., Bonnyay D., Leopold P.L., Merritt R., et al. Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses. Journal of Virology 2004, 78:2572-2580.
425. Worgall S., Krause A., Rivara M., Hee K.-K., Vintayen E.V., Hackett N.R., et al. Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid. The Journal of Clinical Investigation 2005, 115:1281-1289.
426. Wu H., Curiel D.T. Fiber-modified adenoviruses for targeted gene therapy. Methods in Molecular Biology 2008, 434:113-132.
427. Wu H., Han T., Belousova N., Krasnykh V., Kashentseva E., Dmitriev I., et al. Identification of sites in adenovirus hexon for foreign peptide incorporation. Journal of Virology 2005, 79:3382-3390.
428. Wu H., Seki T., Dmitriev I., Uil T., Kashentseva E., Han T., et al. Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency. Human Gene Therapy 2002, 13:1647-1653.
429. Wu E., Trauger S.A., Pache L., Mullen T.-M., von Seggern D.J., Siuzdak G., et al. Membrane cofactor protein is a receptor for adenoviruses associated with epidemic keratoconjunctivitis. Journal of Virology 2004, 78:3897-3905.
430. Xia D., Henry L.J., Gerard R.D., Deisenhofer J. Crystal structure of the receptor-binding domain of adenovirus type 5 fiber protein at 1.7 A resolution. Structure 1994, 2:1259-1270.
431. Xiong J., Sun W.J., Wang W.F., Liao Z.K., Zhou F.X., Kong H.Y., et al. Novel, chimeric, cancer-specific, and radiation-inducible gene promoters for suicide gene therapy of cancer. Cancer 2012, 118:536-548.
432. Xu Y., Liu Z., Kong H., Sun W., Liao Z., Zhou F., et al. Co-expression of interleukin 12 enhances antitumor effects of a novel chimeric promoter-mediated suicide gene therapy in an immunocompetent mouse model. Biochemical and Biophysical Research Communications 2011, 412:763-768.
433. Yamaguchi T., Kawabata K., Koizumi N., Sakurai F., Nakashima K., Sakurai H., et al. Role of MyD88 and TLR9 in the innate immune response elicited by serotype 5 adenoviral vectors. Human Gene Therapy 2007, 18:753-762.
434. Yamamoto M., Curiel D.T. Current issues and future directions of oncolytic adenoviruses. Molecular Therapy 2010, 18:243-250.
435. Yang S.-C., Hillinger S., Riedl K., Zhang L., Zhu L., Huang M., et al. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clinical Cancer Research 2004, 10:2891-2901.
436. Ye Z., Shi M., Chan T., Sas S., Xu S., Xiang J. Engineered CD8+ cytotoxic T cells with fiber-modified adenovirus-mediated TNF-alpha gene transfection counteract immunosuppressive interleukin-10-secreting lung metastasis and solid tumors. Cancer Gene Therapy 2007, 14:661-675.
437. Youil R., Toner T.J., Su Q., Chen M., Tang A., Bett A.J., et al. Hexon gene switch strategy for the generation of chimeric recombinant adenovirus. Human Gene Therapy 2002, 13:311-320.
438. Yu H., Kortylewski M., Pardoll D. Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment. Nature Reviews. Immunology 2007, 7:41-51.
439. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nature Reviews. Cancer 2009, 9:798-809.
440. Zamai L., Ponti C., Mirandola P., Gobbi G., Papa S., Galeotti L., et al. NK cells and cancer. Journal of Immunology 2007, 178:4011-4016.
441. Zhai Y., Yang J.C., Kawakami Y., Spiess P., Wadsworth S.C., Cardoza L.M., et al. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. Journal of Immunology 1996, 156:700-710.
442. Zhang Y., Bergelson J.M. Adenovirus receptors. Journal of Virology 2005, 79:12125-12131.
443. Zhang S.-N., Choi I.-K., Huang J.-H., Yoo J.-Y., Choi K.-J., Yun C.-O. Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF. Molecular Therapy 2011, 19:1558-1568.
444. Zhang X., Kedl R.M., Xiang J. CD40 ligation converts TGF-beta-secreting tolerogenic CD4-8- dendritic cells into IL-12-secreting immunogenic ones. Biochemical and Biophysical Research Communications 2009, 379:954-958.
445. Zhang L., Tang Y., Akbulut H., Zelterman D., Linton P.-J., Deisseroth A.B. An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:15101-15106.
446. Zhao X., Bose A., Komita H., Taylor J.L., Kawabe M., Chi N., et al. Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens. Molecular Therapy 2011, 19:805-814.
447. Zhu J., Huang X., Yang Y. Innate immune response to adenoviral vectors is mediated by both toll-like receptor-dependent and -independent pathways. Journal of Virology 2007, 81:3170-3180.
448. Zhu J., Huang X., Yang Y. A critical role for type I IFN-dependent NK cell activation in innate immune elimination of adenoviral vectors in vivo. Molecular Therapy 2008, 16:1300-1307.
449. Zhu J., Huang X., Yang Y. NKG2D is required for NK cell activation and function in response to E1-deleted adenovirus. Journal of Immunology 2010, 185:7480-7486.
450. Zitvogel L., Kepp O., Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nature Reviews. Clinical Oncology 2011, 8:151-160.